Navigation Links
Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
Date:2/3/2009

QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), announced today that its Neurobionix division has obtained CE Mark approval for its Neurostep(TM) System, the first ever approval for a closed-loop system (CLS) used on peripheral nerves. CE Mark represents regulatory approval needed for the sale of the Neurostep(TM) in any of the Member States of the European Union.

The Neurostep(TM), a fully implantable investigational neuromodulation product designed to treat gait disorders (e.g., foot drop), is the first CLS product aimed at using the patient's own nervous system as the source for detection of intention to move and control their leg. Contrary to other systems that use surrogates such as external sensors, the Neurostep(TM) detects intrinsic muscle activities and surface sensation events from the nerve signals delivered to the spine and brain. This information is then used as the trigger for intervention through neurostimulation, as needed, to complete function. We believe that patients implanted with the Neurostep(TM) will experience remedy to their foot drop and an improved walking pattern that should contribute to give them more independent mobility and a healthier lifestyle.

CE Mark approval gives the Neurobionix division the ability to train and educate physicians in preparation for market release of the Neurostep(TM) System, which is planned for late 2009 in the European Union. The clearance to enter the European market allows the Neurobionix division to increase its market development activity by identification and education of hospitals and physicians that would introduce this new solution to patients in the most expedient manner.

"The approval of the Neurostep(TM) System marks a major milestone in the repositioning of the Neurobionix division into a full function organization that can develop and deliver products of a distinctive value for the market", said Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division. He further said, "We feel confident that we can build on this success to enable commercial launch of the Neurostep(TM) System in the European market in 2009".

While the Neurostep(TM) System is not currently available in the United States, Victhom is planning to engage with the U.S. Food and Drug Administration (FDA) to pursue plans for bringing this new solution for foot drop therapy to patients in the United States.

"Accomplishing CE Mark approval is the latest step in what continues to be the steady advance toward commercialization of the Neurostep(TM)", said Mr. Normand Rivard, Acting President of the Company. "These recent accomplishments are an indication of our commitment to this business and the ability of the Company to deliver on its scientific and business objectives", he added.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
2. Victhom to Participate in the OneMedPlace Finance Forum
3. Victhom Announces Launch of Enhanced Company Website
4. Victhom announces the completion of the second phase of the apnea therapy development
5. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
6. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
7. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
10. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):